Fusion Pharmaceuticals Investor Relations Material

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company headquartered in Hamilton, Canada, focusing on the development of radiopharmaceuticals as precision medicines. The company's primary efforts are directed towards developing treatments that utilize alpha particle emitting isotopes to selectively target and destroy tumor cells. Fusion Pharmaceuticals leverages its Targeted Alpha Therapies (TAT) platform, which facilitates the connection of these isotopes to various targeting molecules, aiming to deliver alpha particle payloads directly to tumors. This approach underpins its research and insights into the chemistry and biology of alpha-emitting radiopharmaceuticals, alongside its capabilities in target identification, candidate generation, manufacturing, and supply chain. Its shares are listed on the Nasdaq.